Lex, I believe the next one is TAVR, then followed by the pericardium patch to cover the brain but the hernia mesh I think is the fastest ROI (Return on investment) and lowest hanging fruit. I do believe that ADMEDUS is in first place for the commencement of the pelvic floor procedure and I believe that the vaginal sling procedure market has opened up for ADMEDUS to take advantage of the Johnson & Johnson defects and also take over their mesh products.
Lex don't forget that the VasculCel market is open for ADMEDUS with Baxter, the biggest player in VasculCel withdrawing from the market. Remember that the ADAPT technology started as a patch for the hole in the heart repair. And the same ADAPT technology is proven for the rest of the body. There is no tissue company to compare ADMEDUS to for it is the future of tissue.
"Take a Closer Look", page-646
-
- There are more pages in this discussion • 582 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.51 |
Change
-0.490(3.27%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.00 | $14.51 | $28.23K | 1.919K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 281 | $14.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.99 | 1034 | 3 |
View Market Depth
| Last trade - 10.16am 15/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |